Treatment-related severe oral mucositis increases cancer costs

2021 ◽  
Vol 1847 (1) ◽  
pp. 11-11
Author(s):  
JEFFERSON FREIRE CARDOSO ◽  
REBEKA THIARA NASCIMENTO DOS SANTOS ◽  
CÉLIA MARIA BOLOGNESE FERREIRA ◽  
JECONIAS CAMARA ◽  
TATIANA NAYARA LIBORIO

Author(s):  
Sergio Ghirardo ◽  
Laura De Nardi ◽  
Alberto Tommasini ◽  
Egidio Barbi ◽  
Gianluca Tornese

: We describe the case of an 11-year-old boy affected by chronic granulomatous disease complicated by a Crohn’s like colitis needing prolonged treatment with oral corticosteroids. His therapy for the control of severe oral mucositis was based on topical clobetasol, which did not decrease once the steroids were discontinued. Two years after the oral interruption of the steroids, cushingoid characteristics persisted, the cause of which, after a thorough investigation, was found to be the persistence of the topical clobetasol oral gel. Several studies investigated the efficacy of topical clobetasol for immuno-related mucositis, but little is known about its pharmacokinetics and side effects. In this report, we have reviewed the literature, defining a maximum putative dose of clobetasol mucosal gel to avoid Cushing syndrome.


2018 ◽  
Vol 65 (8) ◽  
pp. e27098 ◽  
Author(s):  
Margherita Gobbo ◽  
Federico Verzegnassi ◽  
Luca Ronfani ◽  
Davide Zanon ◽  
Fraia Melchionda ◽  
...  

Author(s):  
Lecidamia Cristina Leite Damascena ◽  
Nyellisonn Nando Nóbrega de Lucena ◽  
Isabella Lima Arrais Ribeiro ◽  
Tarciana Liberal Pereira ◽  
Luiz Medeiros Araújo Lima-Filho ◽  
...  

This paper investigates the occurrence of severe oral mucositis and associated factors in blood and solid cancer pediatric patients subjected to cancer treatment, using a survival analysis. A longitudinal, descriptive, observational and inductive study of 142 pediatric patients aged from 0 to 19 years was conducted from 2013 to 2017. Data were collected using a form to record the sociodemographic characteristics and health-related aspects of patients and the modified Oral Assessment Guide (OAG). Survival analysis was performed using the Kaplan–Meier method and Cox semiparametric model. The median times to occurrence of severe oral mucositis were 35.3 and 77.1 days for patients with hematologic malignancies and solid tumors, respectively. The Cox model showed that white cell changes and platelet counts as well as the use of natural chemotherapeutic agents are risk factors for the occurrence of oral mucositis among patients with hematologic malignancies. Nonetheless, among patients with solid tumors, the occurrence of oral mucositis was associated with female sex, mixed ethnicity, the presence of metastasis, abnormal creatinine levels, a combination of chemotherapy, radiotherapy, and surgery, and the administration of chemotherapeutic agents included in the miscellaneous group. The time to occurrence of severe oral mucositis and its associated factors varied according to cancer type.


Sign in / Sign up

Export Citation Format

Share Document